Geron (GERON) shares surge 6.72% on updated guidance highlighting RYTELO expansion and Phase 3 trial progress

Geron’s shares surged 6.7164% in pre-market trading on January 13, 2026, signaling investor confidence in the biotech firm’s strategic direction. The pre-market rally followed the company’s updated guidance for the year, which outlined key priorities and financial projections.

The firm highlighted RYTELO’s commercial expansion as a core focus, aiming to scale U.S. sales while pursuing international market opportunities.

Additionally, Geron announced plans to advance its Phase 3 IMpactMF trial, a critical milestone that could strengthen the drug’s long-term potential. Financially, the company forecast RYTELO revenue of $220–240 million for 2026, with operating expenses aligned at $230–240 million, reflecting disciplined cost management amid growth initiatives.

Strategic restructuring efforts, including operational streamlining and resource reallocation, were also emphasized as part of Geron’s roadmap. These steps, combined with a clear revenue outlook and therapeutic pipeline progress, appear to have driven the pre-market momentum, reinforcing the stock’s appeal to investors seeking biotech sector exposure.

As the company moves forward with these plans, the market will be closely watching the impact of its restructuring and revenue projections. Investors who entered the position before the market opened may now be evaluating the long-term potential of this trade, given the firm’s updated guidance and forward-looking statements.